Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8


SOX10 Distinguishes Pilocytic and Pilomyxoid Astrocytomas From Ependymomas but Shows No Differences in Expression Level in Ependymomas From Infants Versus Older Children or Among Molecular Subgroups.

Kleinschmidt-DeMasters BK, Donson AM, Richmond AM, Pekmezci M, Tihan T, Foreman NK.

J Neuropathol Exp Neurol. 2016 Apr;75(4):295-8. doi: 10.1093/jnen/nlw010. Epub 2016 Mar 4.


ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.

Wilzén A, Krona C, Sveinbjörnsson B, Kristiansson E, Dalevi D, Øra I, De Preter K, Stallings RL, Maris J, Versteeg R, Nilsson S, Kogner P, Abel F.

Mol Cancer. 2013 Jul 8;12(1):70. doi: 10.1186/1476-4598-12-70.


The molecular biology of WHO grade I astrocytomas.

Marko NF, Weil RJ.

Neuro Oncol. 2012 Dec;14(12):1424-31. doi: 10.1093/neuonc/nos257. Epub 2012 Oct 22. Review.


Developmental regulation of microRNA expression in Schwann cells.

Gokey NG, Srinivasan R, Lopez-Anido C, Krueger C, Svaren J.

Mol Cell Biol. 2012 Jan;32(2):558-68. doi: 10.1128/MCB.06270-11. Epub 2011 Nov 7.


The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Amin DN, Campbell MR, Moasser MM.

Semin Cell Dev Biol. 2010 Dec;21(9):944-50. doi: 10.1016/j.semcdb.2010.08.007. Epub 2010 Sep 9. Review.


Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity.

Keating AK, Kim GK, Jones AE, Donson AM, Ware K, Mulcahy JM, Salzberg DB, Foreman NK, Liang X, Thorburn A, Graham DK.

Mol Cancer Ther. 2010 May;9(5):1298-307. doi: 10.1158/1535-7163.MCT-09-0707. Epub 2010 Apr 27.


The ERBB3 receptor in cancer and cancer gene therapy.

Sithanandam G, Anderson LM.

Cancer Gene Ther. 2008 Jul;15(7):413-48. doi: 10.1038/cgt.2008.15. Epub 2008 Apr 11. Review.

Supplemental Content

Support Center